Cargando…

Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems

BACKGROUND: Emulsions on the basis of Perfluorohexyloctane (F6H8), a semifluorinated alkane (SFA), have shown to dissolve and transport highly lipophilic compounds. It is unknown how F6H8-containing emulsions (F6H8-cEM) interact with compartment blood, the reticuloendothelial system (RES), or influe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsagogiorgas, Charalambos, Anger, Friedrich, Beck, Grietje, Breedijk, Annette, Yard, Benito, Hoeger, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602054/
https://www.ncbi.nlm.nih.gov/pubmed/31417241
http://dx.doi.org/10.2147/DDDT.S195954
_version_ 1783431337060859904
author Tsagogiorgas, Charalambos
Anger, Friedrich
Beck, Grietje
Breedijk, Annette
Yard, Benito
Hoeger, Simone
author_facet Tsagogiorgas, Charalambos
Anger, Friedrich
Beck, Grietje
Breedijk, Annette
Yard, Benito
Hoeger, Simone
author_sort Tsagogiorgas, Charalambos
collection PubMed
description BACKGROUND: Emulsions on the basis of Perfluorohexyloctane (F6H8), a semifluorinated alkane (SFA), have shown to dissolve and transport highly lipophilic compounds. It is unknown how F6H8-containing emulsions (F6H8-cEM) interact with compartment blood, the reticuloendothelial system (RES), or influence injured organs in vivo. The current study was conducted to investigate the in vitro biocompatibility of F6H8-cEM and their drug delivery properties. Afterward, an in vivo study was performed as a proof-of-concept study in a rat model of acute kidney injury (AKI), which focused on the potential influence of F6H8-cEM on inflammation in an injured organ. METHODS: Two different F6H8-cEM were stabilized by the emulsifying agents Poloxamer 188 (Pluronic(®) F68) or lecithin (S75). The two resulting emulsions F6H8-Pluronic or F6H8-lecithin were tested in vitro for the potential modulation of acute inflammation via whole blood assay, FACS, and ELISA. Antioxidant capacity and drug delivery properties were measured with an oxidation assay. Secondly, AKI was induced in the rats, which were treated with the F6H8-lecithin emulsion. Renal function and inflammation were assessed. RESULTS: Both F6H8-cEM were phagocytized by monocytes and both dose-dependently affected apoptosis (Annexin V binding) in monocytes. TNF-α expression increased dose-dependency for F6H8-Pluronic emulsion but not for F6H8-lecithin in a whole blood assay. Both F6H8-cEM were able to carry α-tocopherol as a model drug. Animals with AKI treated with the F6H8-lecithin emulsion showed a significantly better renal function and less infiltration of inflammatory cells in renal tissue compared to the control, while inflammatory markers in renal tissue, except HO-1, were not affected by F6H8-lecithin. CONCLUSIONS: Pluronic(®) F68 does not seem suitable as a biocompatible surfactant for F6H8-cEM. The injured kidney was not negatively influenced by the F6H8-lecithin emulsion. Lecithin-stabilized F6H8-cEM could be tested for preclinical studies as a carrier system for lipophilic agents.
format Online
Article
Text
id pubmed-6602054
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66020542019-08-15 Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems Tsagogiorgas, Charalambos Anger, Friedrich Beck, Grietje Breedijk, Annette Yard, Benito Hoeger, Simone Drug Des Devel Ther Original Research BACKGROUND: Emulsions on the basis of Perfluorohexyloctane (F6H8), a semifluorinated alkane (SFA), have shown to dissolve and transport highly lipophilic compounds. It is unknown how F6H8-containing emulsions (F6H8-cEM) interact with compartment blood, the reticuloendothelial system (RES), or influence injured organs in vivo. The current study was conducted to investigate the in vitro biocompatibility of F6H8-cEM and their drug delivery properties. Afterward, an in vivo study was performed as a proof-of-concept study in a rat model of acute kidney injury (AKI), which focused on the potential influence of F6H8-cEM on inflammation in an injured organ. METHODS: Two different F6H8-cEM were stabilized by the emulsifying agents Poloxamer 188 (Pluronic(®) F68) or lecithin (S75). The two resulting emulsions F6H8-Pluronic or F6H8-lecithin were tested in vitro for the potential modulation of acute inflammation via whole blood assay, FACS, and ELISA. Antioxidant capacity and drug delivery properties were measured with an oxidation assay. Secondly, AKI was induced in the rats, which were treated with the F6H8-lecithin emulsion. Renal function and inflammation were assessed. RESULTS: Both F6H8-cEM were phagocytized by monocytes and both dose-dependently affected apoptosis (Annexin V binding) in monocytes. TNF-α expression increased dose-dependency for F6H8-Pluronic emulsion but not for F6H8-lecithin in a whole blood assay. Both F6H8-cEM were able to carry α-tocopherol as a model drug. Animals with AKI treated with the F6H8-lecithin emulsion showed a significantly better renal function and less infiltration of inflammatory cells in renal tissue compared to the control, while inflammatory markers in renal tissue, except HO-1, were not affected by F6H8-lecithin. CONCLUSIONS: Pluronic(®) F68 does not seem suitable as a biocompatible surfactant for F6H8-cEM. The injured kidney was not negatively influenced by the F6H8-lecithin emulsion. Lecithin-stabilized F6H8-cEM could be tested for preclinical studies as a carrier system for lipophilic agents. Dove 2019-06-27 /pmc/articles/PMC6602054/ /pubmed/31417241 http://dx.doi.org/10.2147/DDDT.S195954 Text en © 2019 Tsagogiorgas et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tsagogiorgas, Charalambos
Anger, Friedrich
Beck, Grietje
Breedijk, Annette
Yard, Benito
Hoeger, Simone
Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title_full Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title_fullStr Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title_full_unstemmed Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title_short Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems
title_sort impact of different emulsifiers on biocompatibility and inflammatory potential of perfluorohexyloctane (f6h8) emulsions for new intravenous drug delivery systems
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602054/
https://www.ncbi.nlm.nih.gov/pubmed/31417241
http://dx.doi.org/10.2147/DDDT.S195954
work_keys_str_mv AT tsagogiorgascharalambos impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems
AT angerfriedrich impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems
AT beckgrietje impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems
AT breedijkannette impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems
AT yardbenito impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems
AT hoegersimone impactofdifferentemulsifiersonbiocompatibilityandinflammatorypotentialofperfluorohexyloctanef6h8emulsionsfornewintravenousdrugdeliverysystems